Michael H. Kagey

8.5k total citations · 2 hit papers
34 papers, 5.8k citations indexed

About

Michael H. Kagey is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Michael H. Kagey has authored 34 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in Michael H. Kagey's work include Wnt/β-catenin signaling in development and cancer (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Gastric Cancer Management and Outcomes (8 papers). Michael H. Kagey is often cited by papers focused on Wnt/β-catenin signaling in development and cancer (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Gastric Cancer Management and Outcomes (8 papers). Michael H. Kagey collaborates with scholars based in United States, China and South Korea. Michael H. Kagey's co-authors include Peter B. Rahl, David A. Orlando, Denes Hnisz, Charles Y. Lin, Warren A. Whyte, Brian J. Abraham, Richard A. Young, Richard A. Young, Jamie J. Newman and David Wotton and has published in prestigious journals such as Nature, Cell and Nature Communications.

In The Last Decade

Michael H. Kagey

32 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes

2013 2.7k citations Warren A. Whyte, David A. Orlando et al. Cell profile →
Mediator and cohesin connect gene expression and chromatin architecture

2010 1.4k citations Michael H. Kagey, Jamie J. Newman et al. Nature profile →

Peers

Countries citing papers authored by Michael H. Kagey

Since Specialization

Citations

This map shows the geographic impact of Michael H. Kagey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Kagey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Kagey more than expected).

Fields of papers citing papers by Michael H. Kagey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Kagey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Kagey. The network helps show where Michael H. Kagey may publish in the future.

Co-authorship network of co-authors of Michael H. Kagey

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Kagey. A scholar is included among the top collaborators of Michael H. Kagey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Kagey. Michael H. Kagey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B 2025 ·Nature Communications ·Keun Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do‐Youn Oh, Hope E. Uronis, Sun Jin Sym, Mohamad Bassam Sonbol, Khaldoun Almhanna, Mohamedtaki Abdulaziz Tejani, (unknown), Michael H. Kagey, (unknown), (unknown), Cynthia A. Sirard, (unknown), Jaffer A. Ajani, Samuel J. Klempner	0
2	DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish 2024 ·Journal of Clinical Oncology ·Samuel J. Klempner, Mohamad Bassam Sonbol, Zev A. Wainberg, Hope E. Uronis, Vi K. Chiu, Aaron J. Scott, (unknown), Mohamedtaki Abdulaziz Tejani, Vincent Chung, (unknown), (unknown), Ying Zhang, Michael H. Kagey, Jason Baum, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani	12
3	DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma 2023 ·Gynecologic Oncology ·Rebecca C. Arend, (unknown), C. de Castro, Ursula A. Matulonis, Erika Hamilton, (unknown), (unknown), Howard M. Goodman, Linda Duska, Haider Mahdi, Adam C. ElNaggar, Michael H. Kagey, Amy Liu, (unknown), Lisa Barroilhet, William E. Bradley, Jasgit C. Sachdev, Cynthia A. Sirard, David M. O’Malley, Michael J. Birrer	15
4	DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN ‐01 2022 ·Liver International ·Edward J. Jarman, (unknown), (unknown), (unknown), (unknown), Daniel Soong, (unknown), (unknown), (unknown), William Cambridge, David H. Wilson, Michael H. Kagey, Walter Newman, Jeffrey W. Pollard, Luke Boulter	15
5	Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors 2021 ·Scientific Reports ·Charles C. Caldwell, James B. Rottman, (unknown), (unknown), (unknown), (unknown), Vitria Adisetiyo, Michael Haas, Heidi Heath, Walter Newman, Jason Baum, Roberto Gianani, Michael H. Kagey	11
6	Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy 2021 ·Gynecologic Oncology ·Rebecca C. Arend, Cesar M. Castro, Ursula A. Matulonis, Erika Hamilton, Camille C. Gunderson, (unknown), Howard M. Goodman, Linda Duska, Haider Mahdi, Adam C. ElNaggar, Michael H. Kagey, Lisa Barroilhet, William H. Bradley, Jasgit C. Sachdev, Cynthia A. Sirard, David M. O’Malley, Michael J. Birrer	1
7	1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial 2021 ·Annals of Oncology ·Samuel J. Klempner, Cynthia A. Sirard, (unknown), V.K. Chiu, Devalingam Mahalingam, Hope E. Uronis, Michael H. Kagey, (unknown), Farshid Dayyani, Jin Ho Song, (unknown), (unknown), (unknown), Mohamad Bassam Sonbol, Aaron J. Scott, Zev A. Wainberg, Jaffer A. Ajani	3
8	Abstract PO036: Patients with recurrent epithelial endometrial cancers (EEC) and Wnt signaling alterations demonstrated greater clinical benefit when treated with DKN-01 monotherapy 2021 ·Clinical Cancer Research ·Rebecca C. Arend, Cesar M. Castro, (unknown), (unknown), (unknown), Michael H. Kagey, William H. Bradley, Jasgit C. Sachdev, Cynthia A. Sirard, David M. O’Malley	0
9	mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment 2020 ·Molecular Cancer Research ·Michael Haas, Michael H. Kagey, Heidi Heath, (unknown), James B. Rottman, Walter Newman	52
10	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer 2020 ·Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	46
11	Abstract 1710: DKN-01, a therapeutic DKK1 neutralizing antibody, has immune modulatory activity in nonclinical tumor models 2018 ·Cancer Research ·Michael Haas, Heidi Heath, Yinyuan Wu, Xinjun Zhang, Cynthia A. Sirard, Xi He, Walter Newman, Michael H. Kagey	3
12	Biomarker studies in a phase I trial of DKN-01 in advanced esophageal cancer. 2017 ·Journal of Clinical Oncology ·John H. Strickler, Michael H. Kagey, Cynthia A. Sirard, (unknown), Jorge A. Almenara, Celeste N. Powers, Johanna C. Bendell	3
13	Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC) 2015 ·Molecular Cancer Therapeutics ·Geoffrey I. Shapiro, Afshin Dowlati, Patricia LoRusso, Joseph P. Eder, (unknown), T. Khanh, Michael H. Kagey, Cynthia A. Sirard, James E. Bradner, Steven B. Landau	37
14	Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes breakdown → 2013 ·Cell ·Warren A. Whyte, David A. Orlando, Denes Hnisz, Brian J. Abraham, Charles Y. Lin, Michael H. Kagey, Peter B. Rahl, (unknown), Richard A. Young	2677
15	Mediator and cohesin connect gene expression and chromatin architecture breakdown → 2010 ·Nature ·Michael H. Kagey, Jamie J. Newman, Steve Bilodeau, Ye Zhan, David A. Orlando, Nynke L. van Berkum, Christopher C. Ebmeier, (unknown), Peter B. Rahl, Stuart S. Levine, Dylan J. Taatjes, Job Dekker, Richard A. Young	1430
16	A Role for Non-Covalent SUMO Interaction Motifs in Pc2/CBX4 E3 Activity 2010 ·PLoS ONE ·(unknown), Tiffany A. Melhuish, Michael H. Kagey, (unknown), Andrew D Sharrocks, David Wotton	67
17	Inhibition of CtBP1 Activity by Akt-mediated Phosphorylation 2010 ·Journal of Molecular Biology ·(unknown), Michael H. Kagey, Tiffany A. Melhuish, Shannon Powers, Brad J. Zerlanko, David Wotton	12
18	SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state 2009 ·Genes & Development ·Steve Bilodeau, Michael H. Kagey, Garrett M. Frampton, Peter B. Rahl, Richard A. Young	262
19	Multiple activities contribute to Pc2 E3 function 2004 ·The EMBO Journal ·Michael H. Kagey, Tiffany A. Melhuish, Shannon Powers, David Wotton	62
20	The Polycomb Protein Pc2 Is a SUMO E3 2003 ·Cell ·Michael H. Kagey, Tiffany A. Melhuish, David Wotton	457

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact